|
28 June 2001. The two most prominent genes linked to inherited,
monogenic Parkinson's disease-α-synuclein and parkin-are generally
thought to be unconnected to each other because the forms of PD they
cause are clinically and neuropathologically different. Yet in an
article posted today on Science Express (http://www.sciencexpress.org),
co-first authors Hideki Shimura and Michael Schlossmacher, working with
Dennis Selkoe and Kenneth Kosik at Harvard Medical School's Center for
Neurologic Diseases, report that the two proteins interact in a
biochemical reaction. Moreover, they suggest that this reaction may
underlie the aggregation of α-synuclein in conventional PD as well.
Their work centers on protein degradation. In this cascade of events, a
series of enzymes dubbed E1, E2, and E3 activate and attach a chain of
ubiquitin proteins to a substrate, tagging it for destruction in the
proteasome. Last year Shimura et al. had shown parkin to be an E3
ligase. This and other findings raised the possibility that wildtype
parkin might ubiquitinate α-synuclein, and that disease-linked
mutations in parkin prevent this step toward the protein's proper
disposal, said Schlossmacher. (α-synuclein is the abundant brain
protein present in the neuronal "Lewy body" inclusions that characterize
the most common, idiopathic form of PD.)
The paper reports four experiments supporting this idea. The authors
found that α-synuclein and parkin co-localize in Lewy bodies of PD
patients. They immunoprecipitated a protein complex from normal human
brain, which contains parkin, an associated E2 enzyme, and a new,
glycosylated form of α-synuclein (α-Sp22) as parkin's substrate.
Next, the authors found that this brain-derived parkin specifically
ubiquitinates α-Sp22 whereas mutant parkin from patients does not.
Finally, the authors report that non-ubiquitinated α-Sp22
accumulated in parkin-deficient brains.
These findings suggest a hypothetical model to explain how inherited and
sporadic forms of PD might arise from different alterations of the same
underlying metabolic pathway, says Schlossmacher. In this view, loss of
parkin would lead to accumulation of α-Sp22, which does not
aggregate but might be neurotoxic. These patients do not have Lewy
bodies but do have early onset of symptoms. In conventional PD,
functioning parkin ubiquitinates α-Sp22 but subsequently,
insufficient degradation would lead to a more gradual accumulation of
polyubiquitinated α-Sp22, which tends to aggregate. These patients
have Lewy bodies and late onset of symptoms.
The authors note that their data parallel findings reported in 1999 by
Huda Zoghbi's group on the pathogenesis of polyglutamine expansions in
the ataxin-1 gene. Mice expressing this mutated gene develop neuronal
inclusions. When bred to lack the ataxin-1-specific E3 ligase, however,
they show fewer inclusions but more severe neurodegeneration.-Gabrielle
Strobel.
Reference:Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of a-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001 July 13;293:263-269. Abstract
|